|9th June 2020||Dietrich A Stephan||1,275||Open or private purchase||$7.73||$9,860.72|
|21st May 2020||Dietrich A Stephan||1,250||Open or private purchase||$8.09||$10,111.00|
|30th April 2020||Dov A Md Goldstein||10,000||Open or private purchase||$6.00||$60,000.00|
|30th April 2020||Eric I Richman||2,500||Open or private purchase||$6.00||$15,000.00|
|30th April 2020||Eric I Richman||8,333||Open or private purchase||$6.00||$49,998.00|
|30th April 2020||Samuel Backenroth||1,000||Open or private purchase||$6.00||$6,000.00|
|30th April 2020||Dietrich A Stephan||10,000||Open or private purchase||$6.00||$60,000.00|
|28th February 2020||Dov A Md Goldstein||7,500||Grant/award etc.||$0.00|
|28th February 2020||Eric I Richman||7,500||Grant/award etc.||$0.00|
|12th July 2019||Dietrich A Stephan||2,547,639||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008.